Dr. Molineaux has been the Chief Executive Officer at Para Therapeutics, Inc., since April 2023. Previously, she was Chief Executive Officer, President and a member of the board of directors of Calithera Biosciences, Inc., since co-founding the company in June 2010 until March 2023. Dr. Molineaux has served as a member of the board of directors of Repare Therapeutics since April 2023, Cyteir Therapeutics, Inc., a clinical-stage DNA repair and synthetic lethality company, from December 2020 until May 2023, and Theravance Biopharma, Inc., a biopharmaceutical company, from April 2015 to April 2022. She has also been a Scientific Advisor to Lightstone Ventures, a private life sciences investment company, since September 2016. Dr. Molineaux co-founded Proteolix, Inc., a privately held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009, until the company’s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009.
Previously, Dr. Molineaux held several senior management positions in the biopharmaceutical industry, including Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases, Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular biology from Johns Hopkins University and completed a postdoctoral fellowship at Columbia University.
How do I contact Susan Molineaux?
The corporate mailing address for Dr. Molineaux and other Geron executives is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. Geron can also be reached via phone at (650) 473-7700 and via email at investor@geron.com. Learn More on Susan Molineaux's contact information.
Has Susan Molineaux been buying or selling shares of Geron?
Susan Molineaux has not been actively trading shares of Geron in the last ninety days. Most recently, Susan Molineaux sold 35,000 shares of the business's stock in a transaction on Monday, May 1st. The shares were sold at an average price of $2.48, for a transaction totalling $86,800.00. Learn More on Susan Molineaux's trading history.
Who are Geron's active insiders?
Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.
Are insiders buying or selling shares of Geron?
During the last twelve months, Geron insiders bought shares 2 times. They purchased a total of 27,500 shares worth more than $46,150.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,562,248 shares worth more than $6,808,003.88. The most recent insider tranaction occured on February, 27th when EVP Scott Alan Samuels bought 15,000 shares worth more than $24,150.00. Insiders at Geron own 3.1% of the company.
Learn More about insider trades at Geron. Information on this page was last updated on 2/27/2025.
